Related Experiment Video

Updated: Jan 29, 2026

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis
10:27

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis

Published on: December 15, 2011

25.0K

Deamidated gliadin peptide in pediatric patients with moderately increased tissue transglutaminase; does it help?

Jane A Dickerson1, Dale Lee2, M Cristina Pacheco3

  • 1Department of Laboratories, Seattle Children's Hospital, United States; Department of Laboratory Medicine, University of Washington, United States.

Clinica Chimica Acta; International Journal of Clinical Chemistry
|February 7, 2019
PubMed

Insights

The deamidated gliadin peptide (DGP) screen is not specific enough to aid biopsy decisions in children with moderately elevated tissue transglutaminase (TTG) IgA levels. Further research is needed to establish its utility in pediatric celiac disease diagnosis.

Area of Science:

  • Pediatric gastroenterology
  • Immunology
  • Celiac disease diagnostics

Background:

  • Deamidated gliadin peptide (DGP) assays are emerging tools for celiac disease diagnosis and monitoring.
  • DGP IgG is recommended for children under 2, but its use in older pediatric populations is not well-established.
  • The diagnostic utility of the DGP screen (IgG + IgA) in conjunction with moderately elevated tissue transglutaminase (TTG) IgA levels remains unstudied.

Purpose of the Study:

  • To evaluate the specificity and utility of the DGP screen in pediatric patients with moderately elevated TTG IgA.
  • To determine if the DGP screen provides additional information to guide biopsy decisions in this patient group.

Main Methods:

  • Retrospective analysis of pediatric cases (January 2015 - October 2017) with TTG IgA levels between >19 and <100.
  • Collected data included DGP screen results and biopsy outcomes.
  • 31 out of 495 screened patients met the inclusion criteria.

Main Results:

  • The DGP screen demonstrated a sensitivity of 87.4% and a specificity of 56% in this cohort.
  • Specificity was notably lower in patients with diabetes.
  • The DGP screen did not significantly improve diagnostic accuracy for guiding biopsy decisions.

Conclusions:

  • The DGP screen lacks sufficient specificity to be a reliable tool for guiding biopsy decisions in pediatric patients with moderately elevated TTG IgA.
  • The findings suggest that the DGP screen does not offer substantial additional diagnostic value in this specific clinical scenario.
  • Further investigation may be warranted to explore the role of DGP in other pediatric celiac disease contexts.
Abstract

Keywords:
CeliacDeamidated gliadin peptide (DGP)LaboratoryPediatricTissue transglutaminase (TTG)

More Related Videos

LERLIC-MS/MS for In-depth Characterization and Quantification of Glutamine and Asparagine Deamidation in Shotgun Proteomics08:01

LERLIC-MS/MS for In-depth Characterization and Quantification of Glutamine and Asparagine Deamidation in Shotgun Proteomics

Published on: April 9, 2017

8.6K
A Protocol for the Production of Gliadin-cyanoacrylate Nanoparticles for Hydrophilic Coating09:01

A Protocol for the Production of Gliadin-cyanoacrylate Nanoparticles for Hydrophilic Coating

Published on: July 8, 2016

7.3K

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
259
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
301
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
223
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
291
Peptide Bonds02:43

Peptide Bonds

A peptide bond covalently attaches amino acids through a dehydration reaction. One amino acid's carboxyl group and another amino acid's amino group combine, releasing a water molecule. The resulting bond is the peptide bond. The products that such linkages form are peptides. As more amino acids join this growing chain, the resulting chain is a polypeptide. Each polypeptide has a free amino group at one end. This end has the N-terminal, or the amino-terminal, and the other end has a free...
82.8K
Increasing Function01:18

Increasing Function

An increasing function exhibits a rise in output values as input values increase. This behavior is depicted graphically as a curve or line that slopes upward from left to right. Such a function satisfies the condition that if x1 < x2, then f(x1) < f(x2), indicating that the function values grow with increasing inputs. This concept is fundamental in understanding growth trends across various domains, such as population dynamics, financial investments, or resource consumption.The...
391